[go: up one dir, main page]

PE20120112A1 - Compuestos heterociclicos inhibidores de topoisomerasas - Google Patents

Compuestos heterociclicos inhibidores de topoisomerasas

Info

Publication number
PE20120112A1
PE20120112A1 PE2011001416A PE2011001416A PE20120112A1 PE 20120112 A1 PE20120112 A1 PE 20120112A1 PE 2011001416 A PE2011001416 A PE 2011001416A PE 2011001416 A PE2011001416 A PE 2011001416A PE 20120112 A1 PE20120112 A1 PE 20120112A1
Authority
PE
Peru
Prior art keywords
alkyl
methyledioxy
ethyl
cancer
heterocyclic compounds
Prior art date
Application number
PE2011001416A
Other languages
English (en)
Inventor
Beverly Teicher
Steven Schmid
Edmond J Lavoie
Original Assignee
Genzyme Corp
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120112(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Univ Rutgers filed Critical Genzyme Corp
Publication of PE20120112A1 publication Critical patent/PE20120112A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE A Y B SON N O CH; W ES N O CH; R3 Y R4 SON H, ALQUILO C1-C6 O R3 Y R4 JUNTOS SON =O, =S, =NH O =N-R2; Y Y Z SON OH, ALCOXILO C1-C6, O, O-C(=O), ENTRE OTROS; R1 ES ALQUILO C1-C6 SUSTITUIDO CON UNO O MAS GRUPOS Rz; R2 ES ALQUILO C1-C6 O ALQUILO C1-C6 SUSTITUIDO. SON COMPUESTOS PREFERIDOS: 11,12-DIHIDRO-2,3-DIMETOXI-8,9-METILENDIOXI-11-[2-(DIMETILAMINO)ETIL]-5,6,11-TRIAZACRISEN-12-ONA, 2,3-DIMETOXI-8,9-METILENDIOXI-11-[(2-DIMETILAMINO)ETILO]-11H-5,6,11-TRIAZA-CRISEN-12-ONA, 8,9-DIMETOXI-2,3-METILENDIOXI-5-[2-(N,N-DIMETILAMINO)ETIL]-5H-DIBENZO[c,h]1,6-NAFTIRIDINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS TOPOISOMERASAS Y SON UTILES EN EL TRATAMIENTO DE CANCER DE COLON, CANCER RENAL, CANCER DE SENO, CANCER PULMONARH1299, ENTRE OTROS
PE2011001416A 2009-01-30 2010-01-29 Compuestos heterociclicos inhibidores de topoisomerasas PE20120112A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14888109P 2009-01-30 2009-01-30
US24087309P 2009-09-09 2009-09-09

Publications (1)

Publication Number Publication Date
PE20120112A1 true PE20120112A1 (es) 2012-02-27

Family

ID=42077313

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001416A PE20120112A1 (es) 2009-01-30 2010-01-29 Compuestos heterociclicos inhibidores de topoisomerasas

Country Status (19)

Country Link
US (1) US20120004235A1 (es)
EP (1) EP2391364A1 (es)
JP (1) JP2012516849A (es)
KR (1) KR20110122141A (es)
CN (1) CN102395368A (es)
AR (1) AR075346A1 (es)
AU (1) AU2010208042A1 (es)
BR (1) BRPI1008155A2 (es)
CA (1) CA2749204A1 (es)
CL (1) CL2011001850A1 (es)
CO (1) CO6410302A2 (es)
EA (1) EA201101140A1 (es)
IL (1) IL213919A0 (es)
MX (1) MX2011008069A (es)
NZ (1) NZ593849A (es)
PE (1) PE20120112A1 (es)
SG (1) SG173454A1 (es)
TW (1) TW201038578A (es)
WO (1) WO2010088544A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2403856E (pt) * 2009-03-06 2013-03-25 Univ Rutgers Derivados de metilendioxibenzo[i]fenantridina utilizados para tratar o cancro
CA3019945A1 (en) 2016-04-04 2017-10-12 Rutgers, The State University Of New Jersey Topoisomerase poisons
CN108690034A (zh) * 2018-01-12 2018-10-23 兰州大学 一种氟化苯并萘啶酮类衍生物、制备方法及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
AU1236401A (en) 1999-10-29 2001-05-14 Rutgers, The State University Of New Jerey Heterocyclic cytotoxic agents
EP1453812B1 (en) * 2001-11-14 2008-08-20 Rutgers, The State University Cytotoxic agents
EP2286812A1 (en) * 2001-11-14 2011-02-23 Rutgers, The State University Solubilized topoisomerase poisons
US6992089B2 (en) * 2002-08-09 2006-01-31 Rutgers, The University Of New Jersey Nitro and amino substituted topoisomerase agents
US6989387B2 (en) * 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents

Also Published As

Publication number Publication date
CO6410302A2 (es) 2012-03-30
CN102395368A (zh) 2012-03-28
EA201101140A1 (ru) 2012-03-30
TW201038578A (en) 2010-11-01
EP2391364A1 (en) 2011-12-07
SG173454A1 (en) 2011-09-29
KR20110122141A (ko) 2011-11-09
CA2749204A1 (en) 2010-08-05
AR075346A1 (es) 2011-03-23
NZ593849A (en) 2014-02-28
WO2010088544A1 (en) 2010-08-05
WO2010088544A8 (en) 2011-07-28
IL213919A0 (en) 2011-07-31
JP2012516849A (ja) 2012-07-26
US20120004235A1 (en) 2012-01-05
BRPI1008155A2 (pt) 2016-03-08
AU2010208042A1 (en) 2011-07-21
MX2011008069A (es) 2011-09-06
CL2011001850A1 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
CY1118199T1 (el) Ενωσεις υποκατεστημενης πυραζολο[1,5] πυριμιδινης ως ενδιαμεσα στη συνθεση αναστολεων κινασης trk
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
PE20120495A1 (es) 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
CR11683A (es) Piridinas y pirazinas como inhibidores de p13k
PH12016502037B1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
GB0607954D0 (en) Organic compounds
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
AR083873A1 (es) Derivados de acido amino-fenil-pentanoico sustituidos como inhibidores de nep
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
CO6150181A2 (es) Compuesto 6-(bencilo sustituido con heterociclo)-4-oxoquinolina y su uso como inhibidor de integrasa vih
EA201270302A1 (ru) Безводные формы производных пиридина
PE20120112A1 (es) Compuestos heterociclicos inhibidores de topoisomerasas
PE20140239A1 (es) Derivados de 1,4-oxazepano
ECSP11011053A (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos

Legal Events

Date Code Title Description
FC Refusal